Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study

ObjectiveA link has been proposed between glucose homeostasis and bone metabolism. Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate.Research Design and MethodsWe conducted...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rikke Viggers, Zheer Al-Mashhadi, Jakob Starup-Linde, Peter Vestergaard
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	diabetes type 2 diabetes bone alendronate bisphosphonate Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/9af584bdb0704c2295da8eb022281271
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9af584bdb0704c2295da8eb022281271
record_format	dspace
spelling	oai:doaj.org-article:9af584bdb0704c2295da8eb0222812712021-11-19T10:18:11ZAlendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study1664-239210.3389/fendo.2021.771426https://doaj.org/article/9af584bdb0704c2295da8eb0222812712021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.771426/fullhttps://doaj.org/toc/1664-2392ObjectiveA link has been proposed between glucose homeostasis and bone metabolism. Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate.Research Design and MethodsWe conducted a population-based nested case-control study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. All cases with a diagnosis of type 2 diabetes between 2008 and 2018 were matched on sex and age with 3 randomly selected controls by incidence-density sampling. Exposure was defined as ever use of alendronate and further grouped as effective and compliant use. ORs were calculated by conditional logistic regression analysis with adjustment for several confounders and test for trend for dose-response relationship.ResultsWe included 163,588 patients with type 2 diabetes and 490,764 matched control subjects with a mean age of 67 years and 55% male subjects. The odds of developing type 2 diabetes were lower among ever users of alendronate (multiple adjusted OR: 0.64 [95% CI 0.62-0.66]). A test for trend suggested a dose-response relationship between longer effective use of alendronate and lower risk of type 2 diabetes.ConclusionThese results suggest a possible protective effect of alendronate in a dose-dependent manner against development of type 2 diabetes.Rikke ViggersRikke ViggersZheer Al-MashhadiZheer Al-MashhadiJakob Starup-LindeJakob Starup-LindePeter VestergaardPeter VestergaardFrontiers Media S.A.articlediabetestype 2 diabetesbonealendronatebisphosphonateDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes type 2 diabetes bone alendronate bisphosphonate Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	diabetes type 2 diabetes bone alendronate bisphosphonate Diseases of the endocrine glands. Clinical endocrinology RC648-665 Rikke Viggers Rikke Viggers Zheer Al-Mashhadi Zheer Al-Mashhadi Jakob Starup-Linde Jakob Starup-Linde Peter Vestergaard Peter Vestergaard Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
description	ObjectiveA link has been proposed between glucose homeostasis and bone metabolism. Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate.Research Design and MethodsWe conducted a population-based nested case-control study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. All cases with a diagnosis of type 2 diabetes between 2008 and 2018 were matched on sex and age with 3 randomly selected controls by incidence-density sampling. Exposure was defined as ever use of alendronate and further grouped as effective and compliant use. ORs were calculated by conditional logistic regression analysis with adjustment for several confounders and test for trend for dose-response relationship.ResultsWe included 163,588 patients with type 2 diabetes and 490,764 matched control subjects with a mean age of 67 years and 55% male subjects. The odds of developing type 2 diabetes were lower among ever users of alendronate (multiple adjusted OR: 0.64 [95% CI 0.62-0.66]). A test for trend suggested a dose-response relationship between longer effective use of alendronate and lower risk of type 2 diabetes.ConclusionThese results suggest a possible protective effect of alendronate in a dose-dependent manner against development of type 2 diabetes.
format	article
author	Rikke Viggers Rikke Viggers Zheer Al-Mashhadi Zheer Al-Mashhadi Jakob Starup-Linde Jakob Starup-Linde Peter Vestergaard Peter Vestergaard
author_facet	Rikke Viggers Rikke Viggers Zheer Al-Mashhadi Zheer Al-Mashhadi Jakob Starup-Linde Jakob Starup-Linde Peter Vestergaard Peter Vestergaard
author_sort	Rikke Viggers
title	Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
title_short	Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
title_full	Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
title_fullStr	Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
title_full_unstemmed	Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
title_sort	alendronate use and risk of type 2 diabetes: a nationwide danish nested case-control study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/9af584bdb0704c2295da8eb022281271
work_keys_str_mv	AT rikkeviggers alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy AT rikkeviggers alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy AT zheeralmashhadi alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy AT zheeralmashhadi alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy AT jakobstaruplinde alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy AT jakobstaruplinde alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy AT petervestergaard alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy AT petervestergaard alendronateuseandriskoftype2diabetesanationwidedanishnestedcasecontrolstudy
_version_	1718420275448512512

Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study

Ejemplares similares